Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $72.50 price target on CRISPR Therapeutics (NASDAQ: CRSP) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE